新科学想法 › 学术文库 › 学术文献 › 浏览文献

Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies

唐唐添加于 2011-11-24 05:10 | 3579 次阅读 | 0 个评论

作者
Ba Q, Hao M, Huang H, Hou J, Ge S, Zhang Z, Yin J, Chu R, Jiang H, Wang F, Chen K, Liu H, Wang H
摘要
Purpose:Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death and iron overload is a significant risk factor in the development of HCC. In this study we investigated the potential application of depriving iron by a novel iron chelator, thiosemicarbazone-24 (TSC24), in HCC treatment. Experimental Design:Two HCC cell lines and HFE knockout (HFE-/-) mice were used to determine iron chelation efficiency of TSC24. The anticancer effects of TSC24 on HCC were analyzed in vitro and in athymic xenograft mouse models. Results:Treatment with TSC24 significantly decreased the cellular iron concentration in hepatoma cells and the serum iron concentration in HFE-/- mice, by blocking iron uptake and interfering with normal regulation of iron levels. Moreover, the viability of HCC cell lines was reduced by TSC24. Confirming the mechanism of the agent, this decrease in viability could be partially rescued by addition of exogenous iron. TSC24 also suppressed tumor growth in athymic mice bearing human HCC xenografts in a concentration dependent manner without apparent toxicity in parallel with a decrease in the serum iron level. Further studies revealed that TSC24 efficiently triggered cell cycle arrest and apoptosis in Hep3B and HepG2 cell lines. Conclusions:TSC24 is a potent iron chelator that suppresses human HCC tumor growth by disrupting iron homeostasis, reducing available iron and triggering cell cycle arrest and apoptosis, without apparent host toxicity at effective doses. Thus, TSC24 shows great potential for the treatment of HCC.
详细资料
- 文献种类: Journal Article
- 期刊名称: Clinical Cancer Research
- 期刊缩写: Clinical Cancer Research
- ISBN: 1078-0432
学科领域生物医药 » 基础医学
所属群组
生物综合医学综合药学综合
相关链接 DOI URL

唐唐的文献笔记订阅

抗肝癌药物研究取得新进展

近日，国际学术期刊《临床癌症研究》（Clinical Cancer Research）在线发表了中科院上海生命科学研究院营养所王慧研究组与上海药物研究所柳红研究组合作的关于抗癌小分子药物研究的最新进展Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies。

肝癌是严重影响人类健康的疾病，居世界肿瘤死因的第三位，开发以肝癌中异常高表达分子为靶点的高特异性抗癌药物具有重要的临床意义。铁是人体必需的微量元素之一，同时铁的过量蓄积是肝癌发生发展的重要危险因素之一，提示铁可以作为一种新的癌症治疗靶点。

王慧组巴乾等研究人员在细胞及动物水平对新型铁螯合剂 TSC24（thiosemicarbazone-24）的铁螯合效率和抗肝癌活性及其分子机理进行了深入探讨，发现TSC24可螯合铁、抑制铁吸收并打破细胞内铁的代谢平衡，造成细胞缺铁，同时诱导肝癌细胞G2/M 周期阻滞，通过Caspase途径诱导细胞凋亡，从而发挥抗肝癌活性。

该研究成果将为肝癌的预防和治疗提供新思路。

该研究课题得到了科技部、国家自然科学基金委、中国科学院和上海市科委的资助。（来源：中科院上海生命科学研究院）

管理选项： 导出文献|

评论(0 人)

求全文推荐收藏

1 人收藏

唐唐

Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies

作 者

摘 要

详细资料

学科领域 生物医药 » 基础医学

所属群组

相关链接 DOI URL

唐唐 的文献笔记 订阅

评论(0 人)

1 人收藏

该用户的其他文献

作者

摘要

学科领域生物医药 » 基础医学

唐唐的文献笔记订阅